PFE News and Headlines - Pfizer Inc

GuruFocus Articles Total 707
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 36

The stock trades with a single-digit multiple despite strong growth rates from products outside of Humira

The last time I looked at AbbVie Inc. (ABBV) was following my early February purchase of the stock. At that time, I felt that shares had at least 30% upside. AbbVie recently reported earnings results, and nothing in the report has changed my thesis on the stock. I still believe that shares can offer at least a 30% increase in share price.

Quarterly highlights

AbbVie reported second-quarter earnings results on July 31. The company’s revenue increased 26.3% to $10.4 billion, beating Wall Street analysts’ estimates by almost $290 million. Adjusted earnings per share improved 8 cents, or 3.5%, to

221 Views    Nathan Parsh    2020-08-02 19:31
Pfizer tops the list

According to the GuruFocus All-in-One Screener as of July 31, the following guru-held companies have high dividend yields and are trading with low price-earnings ratios.

Pfizer

Pfizer Inc.'s (PFE) dividend yield is 3.76% and the payout ratio is 0.52. Over the past 52 weeks, the stock has declined 1.71%. Shares are trading with a price-book ratio of 3.34 and a price-earnings ratio of 15.58. The company’s average yield was 3.55% over the past 10 years.

The pharmaceutical company has a market cap of $218.08 billion. The return on equity of 22.73% and return on assets of 8.68% are outperforming

179 Views    Tiziano Frateschi    2020-07-31 18:40
Company CEO thinks pharma giant should earn reasonable profits on its work

Should the Covid-19 vaccine being developed by Pfizer Inc. (PFE) prove successful, it could give the company a $15 billion shot in the arm.

That’s the potential sales estimated by Bloomberg Intelligence analyst Sam Fazeli for a one-dose regimen of the vaccine, according to a FiercePharma article. Of course, that’s contingent on Pfizer being able to deliver 100 million doses of an effective inoculation.

Pfizer's deal also includes an option for another 500 million doses, RBC Capital Markets analyst Randall Stanicky pointed out, so "investors are increasingly seeing real opportunity here."

Meanwhile, Johnson & Johnson (JNJ), a late entrant to

323 Views    Barry Cohen    2020-07-30 19:22
President Trump’s latest effort to control drug prices seen as more style than substance

It appears drug companies and their investors have little to fear from President Trump’s latest salvo aimed at holding down prescription drug prices.

Last week Trump signed a series of four executive orders he claimed will control pharmaceutical costs. But the action was quickly dismissed by many as being heavy on style and weak on substance. Some of the executive orders are unlikely to ever be implemented. Moreover, the orders require new regulations that ordinarily take months to finalize.

The proposals would help only a small group of people, according to comments by Peter Maybarduk, director of Public Citizen’s Access

75 Views    Barry Cohen    2020-07-29 20:09
Dow Jones gains 0.62%, led by Pfizer

The Dow Jones Industrial Average closed at 27,005.84 on Wednesday with a gain of 165.44 points or 0.62%. The S&P 500 closed at 3,276.02 for a gain of 18.72 points or 0.57%. The Nasdaq Composite closed at 10,706.13 for a gain of 25.76 points or 0.24%. The VIX Volatility Index was lower at 24.41 for a loss of 0.43 points or -1.73%.

Wednesday’s Market Movers

Pfizer and BioNTech received a $1.95 billion order from the U.S. government for the partnership’s Covid-19 vaccine. Pfizer led gains for the day, up nearly 5% and contributing to the Dow’s return for the day.

26 Views    Julie Young    2020-07-22 21:15
Pfizer Inc tops the list

One strategy to come across value opportunities is to screen for stocks with an enticing forward price-earnings ratio.

The following three stocks have a forward price-earnings ratio that stands below the S&P 500 index's historical average of 15. Estimates of future earnings are based on data from Morningstar analysts.

Pfizer Inc

The first company that meets the criteria is Pfizer Inc (PFE), the New York-based drug giant.

Pfizer Inc has a forward price-earnings ratio of 12.8 (versus the industry median of 19.42), which results from Friday’s share price of $36.25 and analyst expectations for earnings per share (EPS)

128 Views    Alberto Abaterusso    2020-07-19 15:11
Some companies may turn to acquisitions to boost revenues

Previously, I listed the 15 members of Big Pharma that are expected to record the highest sales in 2026, as reported by EvaluatePharma. Now we’ll look at the products and strategies that will propel the top five companies’ revenue.


Roche Holding AG (RHHBY)

  • Estimated 2026 sales: $61.9 billion
  • 2019 sales: $48.2 billion
  • 2019 to 2026 CAGR: 3.62%

Although the Swiss company is expected to suffer a $10 billion shortfall when three of its top-selling cancer drugs lose exclusivity, replacements are expected to step into the breach. That was the case in the first quarter, when two

233 Views    Barry Cohen    2020-07-14 21:42
AstraZeneca and Bristol-Myers Squibb's revenues expected to grow the fastest

Thanks to the introduction of drugs in three major disease areas, Roche (RHHBY) is expected to retain its position as the number one member of Big Pharma in terms of sales, according to a report from Evaluate Pharma.

The Swiss company’s revenues are forecast to reach $62 billion in 2026, growing at a compound rate of more than 3.6% from 2019. Pfizer Inc. (PFE) is expected to capture the number two spot with sales of just over $56 billion. Others reaching the $50 billion plus level are Johnson & Johnson (JNJ), Novartis (NVS), AbbVie Inc.(ABBV) and Merck & Co. Inc.

228 Views    Barry Cohen    2020-07-13 21:33
If approved, company’s Roctavian would become first gene therapy for inherited disease

Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.

Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common

231 Views    Barry Cohen    2020-07-09 18:57
While giants like Gilead Sciences and Pfizer are progressing well, many small players have witnessed setbacks in their Covid-19 research

As the world awaits a potential solution to counter the Covid-19 pandemic, a number of pharma and biotech companies have their candidates going through different stages of trials.

The total number of confirmed Covid-19 cases across the globe is nearing the 12 million mark, with over 3 million in the U.S. alone. Governments have thus been putting increasing pressure on scientists and pharmaceutical companies to come up with a drug or a vaccine to handle the situation. The process has been slow, which was expected as a successful treatment has never before been developed for any other type of coronavirus,

245 Views    Ishan Majumdar    2020-07-08 20:50
The company has a strong pipeline of antibody-drug conjugates

Immunomedics (IMMU) has been in the news for a recent change of CEO. The company’s President and CEO Harout Semerjian stepped down and was replaced by Dr. Behzad Aghazadeh.

The company has also been making some fantastic progress on antibody-drug conjugates (ADCs), particularly Trodelvy, which was used to treat its first commerical in the past few weeks. The drug is expected to drive revenues for Immunomedics in 2020.

The company has some promising collaborations with giants such as AstraZeneca (AZN) and Roche (OTCQX:RHHBY). It has also raised funds recently to fund its research for the coming quarters.

In my

230 Views    Ishan Majumdar    2020-07-08 14:29
A drug manufacturer with a high-yield dividend, but some concerning fundamentals

Meet a drug company with an extraordinary return on equity: GlaxoSmithKline PLC (GSK).

GuruFocus GSK return on equity chart

Its return on equity is extremely volatile, ranging from 25.14% for 2016 to 313.03% for 2017. That makes 2019’s return on equity of 61.7% appear almost normal. But, of course, we know few companies have such a high return on investors’ money.

Does that make it an immediate buy stock, especially since its dividend falls into the category of high-yield? More than a dozen gurus apparently think so, and it does have a place on the

229 Views    Robert Abbott    2020-07-06 18:52
Nasdaq up 13.76% for the year

The Dow Jones Industrial Average closed at 25,827.36 on Thursday with a gain of 92.39 points or 0.36%. The S&P 500 closed at 3,130.01 for a gain of 14.15 points or 0.45%. The Nasdaq Composite closed at 10,207.63 for a gain of 53.00 points or 0.52%. The VIX Volatility Index was lower at 27.77 for a loss of 0.85 points or -2.97%.

For the week, the Nasdaq gained 4.6%, the S&P 500 gained 4.0% and the Dow Jones gained 3.3%. For the year, the Nasdaq has a gain of 13.76%, the S&P 500 is down 3.12% and the Dow Jones

43 Views    Julie Young    2020-07-02 21:24
Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades

Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades. The +20% rebound in the 2nd quarter S&P 500 index was the best result achieved since 1998. Moreover, the Dow Jones Industrial Average saw its largest quarterly gain (+18%) since 1987, and the technology-heavy NASDAQ index (+31%) saw the most appreciation since 2001. While a snap-back after a shockingly dismal 1st quarter should come as no surprise to many investors, the pace of this rebound is unlikely to be sustainable at this trajectory, given the challenging economic

54 Views    Wade W. Slome, CFA, CFP    2020-07-02 16:12
The green energy player has fought its way through bankruptcy after the ExxonMobil deal and has delivered solid results

As the world continues to fight the Covid-19 pandemic, one highly promising sector that has been put on the backburner by the investor community is the green energy space. It only appears to be a matter of time before this comes back to focus, which is when companies like FuelCell Energy Inc. (FCEL) will be back in the limelight.

FuelCell Energy is one of the oldest clean energy companies, and it managed to deliver an excellent quarterly result even in the lockdown situation. As it readies itself to issue an additional $75 million worth of stock, the price is falling

183 Views    Ishan Majumdar    2020-06-24 14:23
Biotech’s shares trading near all-time high of $172. It is also working on Covid-19 treatment

On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc. (SRPT) hit their all-time high of more than $172 on June 23.

The share price of the Cambridge, Massachusetts-based biopharmaceutical company has doubled since mid-March. It has a market cap of more than $13 billion.

Sarepta has made a host of deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with Roche (RHHBY), could be worth more than $3 billion.

Sarepta currently has a

165 Views    Barry Cohen    2020-06-23 19:05
The drugmaker offers a dividend yield of almost 4.5%

Pfizer Inc (PFE) has joined the list of High-Yield Dividend Screener & High-Dividend Yield Stocks in Guru's Portfolios.

Based on the share price on Monday, June 22, it offers a dividend yield of 4.43%, more than double the average of the S&P 500, while its share price has been going down—and began going down before Covid-19 was a factor :

GuruFocus Pfizer price chart

Specifically, the price took a dive in the first couple of weeks of July 2019, just before patent protection on the fibromyalgia drug Lyrica expired on July 19th and a generic

1203 Views    Robert Abbott    2020-06-23 18:48
Even with smaller budgets, emerging biotech companies are outpacing Big Pharma in drug discovery

If it’s true that “you have to spend money to make money” and “you get what you pay for,” then investors should pile into the stocks of the pharmaceutical companies plowing the most into research and development.

At the top of that list are Roche (RHHBY), Johnson & Johnson (JNJ), Merck & Co. Inc. (MRK) and Novartis (NVS). Last year, these four--along with six other members of Big Pharma-- spent a collective $82 billion in their quest for new drugs, diagnostics and vaccines, around $4 billion more than the previous year, according to FierceBiotech.

But a word of caution here:

149 Views    Barry Cohen    2020-06-09 19:28
The company’s shareholders have seen stock price soar in the past year

Among the most highly-paid pharmaceutical CEOs in 2019, Vertex Pharmaceuticals Inc.’s (VRTX) Jeffrey Leiden has given shareholders the biggest bang for the buck. Although he was the only the 9th highest paid (out of 15 ranked), under Leiden’s stewardship the company’s share price rose 53% in the past year.

On the other end of the spectrum was Albert Bourla of Pfizer Inc. (PFE), who raked in a paltry $18 million for shareholders. The company’s share price has plummeted more than 15% during the past 12 months.

The list of the 15 highest-paid CEOs in pharma was

186 Views    Barry Cohen    2020-06-08 15:29
My wife and I focus our investments on dividend growth stocks

Due to the timing of contributions to our IRAs, my wife and I were able to make three new stock purchases over the last two weeks. We invest nearly all of our retirement capital in dividend growth stocks, as we plan to live off dividend income when we are able to retire in 20 years or so.

When selecting investments, we look at dividend growth stocks stocks trading below the 10-year average valuation, which gives a margin of safety. Here are the purchases we made and our reasons for doing so.

Pfizer

We purchased shares of Pfizer Inc. (PFE) on

901 Views    Nathan Parsh    2020-05-14 14:33

Headlines Total 521
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

2020-08-02
2:33pm
11:25am
11:00am
9:16am
8:14am
6:44am
2020-08-01
10:44am
6:49am
6:33am
2020-07-31 $ 38.48 (-0.67%)
11:44am
9:04am
6:47am
2020-07-30 $ 38.74 (-1.32%)
2:22pm
11:07am
10:47am
2020-07-29 $ 39.26 (0.62%)
8:49am
2020-07-28 $ 39.02 (3.94%)
4:54pm
4:16pm
1:59pm
12:22pm
12:00pm
9:25am
9:22am
9:17am
8:26am
7:19am
7:05am
7:00am
9:24pm
2020-07-27 $ 37.54 (-0.32%)
12:46pm
12:07pm
11:10am
11:05am
10:03am
9:53am
9:30am
8:14am
2020-07-26
2:33pm
2020-07-25
6:42am
6:14am
2020-07-24 $ 37.66 (-1.95%)
12:12pm
10:18am
10:13am
9:52am
9:27am
2020-07-23 $ 38.41 (-0.39%)
5:07pm
10:18am
10:18am
9:01am
8:30am
2020-07-22 $ 38.56 (5.1%)
4:15pm
10:44am
9:43am
Earnings Data Deluge - www.zacks.com
9:16am
9:15am
9:02am
6:48am
2020-07-21 $ 36.69 (0.52%)
11:31am
9:29am
9:24am
9:07am
8:41am
7:48am
9:27pm
2020-07-20 $ 36.5 (0.69%)
4:45pm
11:38am
9:59am
7:24am
2020-07-19
10:11am
7:55am
2020-07-18
8:07am
6:32am
2020-07-17 $ 36.25 (1.83%)
5:00pm
10:06am
7:47am
6:43am
2020-07-16 $ 35.6 (-0.34%)
10:11am
8:22am
2020-07-15 $ 35.72 (1.39%)
12:32pm
10:38am
9:18am
8:49am
7:32am
6:28am
2020-07-14 $ 35.23 (0.06%)
4:45pm
3:31pm
8:50am
8:45am
7:44am
7:27am
7:11am
7:01am
6:42am
2020-07-13 $ 35.21 (4.08%)
4:44pm
4:33pm
11:31am
8:29am
2020-07-12
1:02pm
2020-07-10 $ 33.83 (1.11%)
2:34pm
9:24am
Total 521
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6